Go to AAD Home
Donate For Public and Patients Store Search

Go to AAD Home
Welcome!
Advertisement
Advertisement

2023 Annual Meeting: Industry Non-CME Programs


Don't miss the latest from industry at the 2023 AAD Annual Meeting!

The Industry Non-CME (INC) Programs at the 2023 AAD Annual Meeting are your chance to learn about the latest innovations directly from industry. At the sponsoring company’s discretion, these sessions present new research findings, showcase specialty innovations, conduct demonstrations, and host lively discussions.

Pre-registration and food & beverage may be provided by the sponsoring company. INC Programs take place after scientific sessions in the evening and are solely developed and delivered by the sponsor. They do not qualify for continuing medical education (CME) credit.

Thursday, March 16

Abbvie logo
Presented by: AbbVie, Platinum sponsor - Save this program to your schedule in the AAD mobile app.
Advancing Therapeutic Conversations

Examining data to confidently support the RINVOQ benefit-risk decision for adult and pediatric patients with refractory moderate to severe atopic dermatitis (AD).

Speaker: Mona Shahriari, MD
When: Thursday, March 16 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Grand Ballroom D | Hilton New Orleans Riverside


Beyond the Scalp: Deciphering the Complexities of Alopecia Areata Diagnosis & Assessment

Pfizer, Inc. logo
Presented by: Pfizer, Inc., Platinum sponsor - Save this program to your schedule in the AAD mobile app.
Alopecia Areata (AA) is much more than a cosmetic condition, requiring a complex and holistic approach to diagnosis and assessment. Join us for a practical session where our faculty will explore several considerations for assessing patients with AA, beyond hair loss alone.

When: Thursday, March 16 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Cypress Ballroom | Marriott Warehouse Arts District Hotel


PeerView Live
Presented by: PeerView Live
Moving Beyond Off-Label Management in Prurigo Nodularis: Looking Toward New Treatment Options

“Moving Beyond Off-Label Management in Prurigo Nodularis: Looking Toward New Treatment Options” will cover the pathophysiology and burdens of disease, as well as new and emerging treatment options. This PeerView “How I Think, How I Treat” symposium features a panel of faculty experts, 3D animation of prurigo nodularis pathophysiology, patient videos, and engaging learner polling, all geared towards preparing learners to address this chronic inflammatory skin condition that is notoriously challenging to manage.

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
When: Thursday, March 16 | 7:00 p.m. Registration | 7:30 p.m. Program
Where: Gravier Ballrooms A-D | Marriott Warehouse Arts District Hotel
View more information and register.


Friday, March 17

Bristol Myers Squibb™
Presented by: Bristol Myers Squibb, Platinum sponsor - Save this program to your schedule in the AAD mobile app.
Join Us to Learn More About SOTYKTUTM (deucravacitinib): Clinical Trial Data and Mechanism of Action

Get to know the efficacy and safety data from the POETYK clinical trials, along with how this product works.

When: Friday, March 17 | 7:00 p.m. Program
Where: Gravier Ballrooms A-D | Marriott Warehouse Arts District Hotel


Sanofi-Regeneron logo
Presented by: Sanofi and Regeneron, Platinum sponsors - Save this program to your schedule in the AAD mobile app.
Prurigo Nodularis and Atopic Dermatitis: Distinct Diseases with Shared and Unique Roles for Type 2 Inflammation

Although atopic dermatitis and prurigo nodularis share certain clinical features such as chronicity and intense itch, and both involve type 2 inflammation, they are nevertheless distinct diseases. In this symposium, we will review distinguishing characteristics of these diseases, including how alterations to skin tissue, neuroimmune axis dysregulation, and local and systemic type 2 inflammation may result in the marked skin signs and symptoms that define prurigo nodularis and atopic dermatitis.

When: Friday, March 17 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Grand Ballroom D | Hilton New Orleans Riverside
View more information and register.


Optimal Treatment of Hidradenitis Suppurativa

Logo for Novartis
Presented by: Novartis Pharmaceuticals Corporation
This symposium explores best practices in the treatment of hidradenitis suppurativa (HS), focusing on high-priority educational topics that were identified in a multi-stakeholder advisory board meeting conducted by Novartis Dermatology Medical Affairs in November 2022. The symposium consists of 5 consecutive short presentations on the following topics:

  • General clinical strategies and guidance regarding biologic use in HS

  • Unmet needs in HS treatment and the “window of opportunity” concept

  • Understanding the heterogeneity of HS severity and the challenge of defining “moderate” HS

  • Approaches to documenting HS for payers and streamlining prior authorization of HS treatments

  • The role of the HS Foundation in overcoming challenges and barriers faced by HS patient

When: Friday, March 17 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Cypress Ballroom | Marriott Warehouse Arts District Hotel


Saturday, March 18

Janssen  logo
Presented by: Janssen Scientific Affairs, LLC, Platinum sponsor - Save this program to your schedule in the AAD mobile app.
Caring for All Colors: Embracing Diverse Skin Tones to Advance Research and Patient Management

Our panel of experts will discuss the current status and progress in diversity in clinical trials and care for people of all colors including novel methods in skin of color research and tips for optimizing cultural sensitivity. Attendees will have an opportunity to ask the faculty questions in an interactive fireside chat.

When: Saturday, March 18 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Cypress Ballroom | Marriott Warehouse Arts District Hotel


More Than Skin-Deep Solutions: The Role of Oral JAK Inhibitors in the Treatment of Atopic Dermatitis

Logo for Answers in CME
Presented by: Answers in CME
Do you have questions about how to effectively use Janus kinase (JAK) inhibitors in patients with moderate-to-severe atopic dermatitis? Join us as two faculty experts provide practical approaches for integrating these novel agents and improving patient quality of life.

This activity is supported by an educational grant from AbbVie.
When: Saturday, March 18 | 6:45 p.m. Registration | 7:00 p.m. Program
Where: Grand Ballroom D | Hilton New Orleans Riverside
View more information and register.


Johnson & Johnson consumer health logo
Presented by: Johnson & Johnson Consumer Inc.
Starting Emollient Use in the First Days after Birth in Infants at Risk for Atopic Dermatitis: What Does the Latest Research Tell Us?

When: Saturday, March 18 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Gravier Ballrooms A-D | Marriott Warehouse Arts District Hotel


Sunday, March 19

Med Learning Group logo
Presented by: Med Learning Group
Moderate-to-Severe Atopic Dermatitis: A Deeper Look at Systemic Therapies

This innovative and engaging animation simulation challenge symposium will improve clinicians’ ability to use assessment tools to evaluate disease burden and severity; compare-and-contrast systemic treatment options for the management of moderate-to-severe Atopic Dermatitis (AD); and develop proactive treatment plans that manage signs and symptoms, minimize disease flares, and improve quality of life in pediatric and adult patients with AD.

This program is supported by an independent medical educational grant from Sanofi and Regeneron Pharmaceuticals.
When: Sunday, March 19 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Grand Ballroom D | Hilton New Orleans Riverside
View more information and register.


Logo for Answers in CME
Presented by: Answers in CME
Exploring Neoadjuvant Immunotherapies for Surgically Resectable Cutaneous Squamous Cell Carcinoma: Targeting Early Intervention to Achieve Best Outcomes

Join us to learn how neoadjuvant immunotherapy fits into the treatment plan for many patients with surgically resectable cutaneous squamous cell carcinoma. Discover why timing matters when giving your patients the best chance of a pathological complete response after resection.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
When: Sunday, March 19 | 6:45 p.m. Registration | 7:00 p.m. Program
Where: Gravier Ballrooms A-D | Marriott Warehouse Arts District Hotel
View more information and register.


The next step in GPP management: Following the IL-36 pathway in generalized pustular psoriasis (GPP)

Boehringer Ingelheim Pharmaceuticals logo
Presented by: Boehringer Ingelheim Pharmaceuticals, Inc.
This symposium will take attendees on a step-by-step journey from the discovery of the IL-36 pathway, through current understanding of its key role in generalized pustular psoriasis (GPP), to use of IL-36 receptor inhibitors for the treatment of GPP flares. Experts will present information on the use of IL-36 receptor inhibitors for the treatment of GPP flares and discuss what is next on the horizon for GPP treatment.

When: Sunday, March 19 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Cypress Ballroom | Marriott Warehouse Arts District Hotel


Monday, March 20

Reframing the Management Approach for Moderate to Severe Atopic Dermatitis

Medscape logo
Presented by: Medscape, LLC.
Are you consistently managing your patients with moderate-to-severe atopic dermatitis or treating the flares as they come? This Ted Talk style symposium will focus on effective, long-term biologic-based strategies for your patients with moderate to severe atopic dermatitis. Don’t miss out!

Supported by an independent educational grant from Lilly.
When: Monday, March 20 | 6:30 p.m. Registration | 7:00 p.m. Program
Where: Jackson Room | Hilton New Orleans Riverside
View more information and register.

Advertisement